Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

The Role of Surgery in the Treatment of Limited Disease Small Cell Lung Cancer Time to Reevaluate

The Role of Surgery in the Treatment of Limited Disease Small Cell Lung Cancer Time to Reevaluate ORIGINAL ARTICLE The Role of Surgery in the Treatment of Limited Disease Small Cell Lung Cancer Time to Reevaluate Eric Lim, FRCS (C-Th), Elizabeth Belcher, FRCS, Yoon Khoong Yap, MRCS, Andrew G. Nicholson, FRCPath, and Peter Goldstraw, FRCS trials reported a current median survival of 17 months and Abstract: Chemo-radiation is considered the standard procedure for data from the Surveillance, Epidemiological and End Results the management of limited disease small-cell lung cancer (SCLC). program of the National Cancer Institute (Bethesda, Mary- Controversy remains as to when surgery should be considered. We land) reported an overall 5 year survival of 10%. sought to determine the survival after complete resection of SCLC Surgery has been considered unsuitable for patients and the prognostic impact of clinical and pathologic stage. with limited stage disease as it had been associated with Methods: A retrospective review was undertaken of patients who overall 5 year survival of less than 5%. Early randomized underwent surgery between 1980 and 2006. Patients were staged trials comparing surgery alone versus radiotherapy reported according to the 6th edition of the Tumor, Node, Metastasis classifica- 4% survival at 2-years in patients randomized to surgery tion of lung cancer, actuarial survival estimated with http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

The Role of Surgery in the Treatment of Limited Disease Small Cell Lung Cancer Time to Reevaluate

Journal of Thoracic Oncology , Volume 3 (11) – Nov 1, 2008

Loading next page...
 
/lp/wolters-kluwer-health/the-role-of-surgery-in-the-treatment-of-limited-disease-small-cell-WZ2d6kF6OQ

References (15)

ISSN
1556-0864
DOI
10.1097/JTO.0b013e318189a860
pmid
18978561
Publisher site
See Article on Publisher Site

Abstract

ORIGINAL ARTICLE The Role of Surgery in the Treatment of Limited Disease Small Cell Lung Cancer Time to Reevaluate Eric Lim, FRCS (C-Th), Elizabeth Belcher, FRCS, Yoon Khoong Yap, MRCS, Andrew G. Nicholson, FRCPath, and Peter Goldstraw, FRCS trials reported a current median survival of 17 months and Abstract: Chemo-radiation is considered the standard procedure for data from the Surveillance, Epidemiological and End Results the management of limited disease small-cell lung cancer (SCLC). program of the National Cancer Institute (Bethesda, Mary- Controversy remains as to when surgery should be considered. We land) reported an overall 5 year survival of 10%. sought to determine the survival after complete resection of SCLC Surgery has been considered unsuitable for patients and the prognostic impact of clinical and pathologic stage. with limited stage disease as it had been associated with Methods: A retrospective review was undertaken of patients who overall 5 year survival of less than 5%. Early randomized underwent surgery between 1980 and 2006. Patients were staged trials comparing surgery alone versus radiotherapy reported according to the 6th edition of the Tumor, Node, Metastasis classifica- 4% survival at 2-years in patients randomized to surgery tion of lung cancer, actuarial survival estimated with

Journal

Journal of Thoracic OncologyWolters Kluwer Health

Published: Nov 1, 2008

There are no references for this article.